Sign in Subscribe

Archive

A collection of 715 issues

Latest

Study Examines Universal Tumor Screening for Lynch Syndrome in Japan

Skip to content The CRC Digest ▪ SCREENING Study Examines Universal Tumor Screening for Lynch Syndrome in Japan A prospective study of 591 patients with stage II/III colorectal cancer in Japan aimed to clarify the clinical utility and cost-effectiveness of universal tumor screening using immunohistochemistry to identify Lynch syndrome, with

KRAS Mutation Subtypes May Influence Response to Neoadjuvant Therapy in Rectal Cancer

Skip to content The CRC Digest ◇ RESEARCH KRAS Mutation Subtypes May Influence Response to Neoadjuvant Therapy in Rectal Cancer A meta-analysis investigated whether different KRAS mutation subtypes affect pathological complete response rates after neoadjuvant chemoradiotherapy in locally advanced rectal cancer. The study examined KRAS mutations within and outside exon 2.

Financial and professional impacts persist for early-onset CRC survivors

Skip to content The CRC Digest Financial and professional impacts persist for early-onset CRC survivors A multicenter study across 7 academic medical centers found that patients diagnosed with colorectal cancer before age 50 experience lasting financial and professional instability, given their developmental stage in establishing careers and families. (Diseases of

AI tool identifies rectal cancer patients who benefit from intensified chemoradiotherapy

Skip to content The CRC Digest ◇ RESEARCH AI tool identifies rectal cancer patients who benefit from intensified chemoradiotherapy A post-hoc analysis of the phase III ARISTOTLE trial found that higher tumor cell density predicted improved survival in locally advanced rectal cancer patients receiving irinotecan-intensified neoadjuvant chemoradiotherapy; researchers developed a free

FDA approves second blood test to help close colorectal cancer screening gap

Skip to content The CRC Digest ● REGULATORY FDA approves second blood test to help close colorectal cancer screening gap The FDA has approved a second blood-based screening test for colorectal cancer, expanding options for patients who may avoid traditional colonoscopy. (AOL.com) This content is informational only and does not

CRC Research Update — August 03, 2026

Today's colorectal cancer research highlights

Stool DNA Tests Offer Higher Sensitivity but Lower Specificity Than FIT

Skip to content The CRC Digest Stool DNA Tests Offer Higher Sensitivity but Lower Specificity Than FIT Multitarget stool DNA tests show higher sensitivity for colorectal cancer and advanced adenomas than FIT, but with lower specificity and higher costs; further evidence is needed on long-term effectiveness and economic sustainability. (Clinical

Symptom Identification Critical for Adults 18-44

Skip to content The CRC Digest Symptom Identification Critical for Adults 18-44 Adults under 45 without access to average-risk screening require a well-defined system for symptom identification and workup to avoid diagnostic delays and worse outcomes. (Cancer Epidemiology, Biomarkers & Prevention) This content is informational only and does not constitute

FIT Remains Cornerstone of Population-Based CRC Screening

Skip to content The CRC Digest ▪ SCREENING FIT Remains Cornerstone of Population-Based CRC Screening Fecal immunochemical testing (FIT) continues to be the foundation of organized colorectal cancer screening programs due to its noninvasive nature, affordability, and proven mortality reduction, though stool DNA tests may serve as complementary options in hybrid

Study Examines Symptoms as Diagnostic Indicators in Adults Under 45

Skip to content The CRC Digest ▪ SCREENING Study Examines Symptoms as Diagnostic Indicators in Adults Under 45 (Cancer Epidemiology, Biomarkers & Prevention) This content is informational only and does not constitute medical advice. Always consult your oncologist or care team. © 2026 The CRC Digest — crcdigest.com